Cover Image
市場調查報告書

黑色素瘤:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Melanoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365182
出版日期 內容資訊 英文 291 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
黑色素瘤:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Melanoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 291 Pages
簡介

本報告提供黑色素瘤的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,主要產品的專利到期伴隨的影響,有力的開發中產品的功效與風險,及預期銷售額等相關調查。

市場預測:黑色素瘤

  • 摘要整理
  • 市場概要與趨勢
  • 價格趨勢與醫療費償付
  • 市場定義和分析方法
  • binimetinib
  • Cotellic (cobimetinib)
  • encorafenib
  • Imlygic (talimogene laherparepvec)
  • Keytruda (pembrolizumab)
  • Mekinist (trametinib)
  • Opdivo (nivolumab)
  • Tafinlar (dabrafenib)
  • Yervoy (ipilimumab)
  • Zelboraf (Vemurafenib)
  • 一次調查技術

治療方法:黑色素瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢

流行病學:黑色素瘤

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:黑色素瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Cotellic
  • 產品簡介:Imlygic
  • 產品簡介:Keytruda
  • 產品簡介:Mekinist
  • 產品簡介:Opdivo
  • 產品簡介:Tafinlar
  • 產品簡介:Yervoy
  • 產品簡介:Zelboraf

開發中產品:黑色素瘤

  • 摘要整理
  • 臨床實驗開發平台概要
  • 產品簡介 (最後階段):binimetinib
  • 產品簡介 (最後階段):encorafenib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5786

Immune checkpoint inhibitors Yervoy, Opdivo, and Keytruda will be the key drivers of growth in the melanoma market.

This report addresses the following questions:

  • How will the patent expiries of key brands impact melanoma market sales?
  • What will differentiate immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda from the rest of the marketed therapies for melanoma?
  • Which marketed drugs or combination therapies will dominate the BRAF mutation-positive melanoma segment?
  • Considering its cost and safety profile, what is the commercial potential of Imlygic?
  • Which pipeline drugs address the unmet needs of NRAS mutation-positive melanoma patients?

TABLE OF CONTENTS

FORECAST: MELANOMA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Pricing and Reimbursement
  • 4. Market Definition and Methodology
  • 5. binimetinib
  • 6. Cotellic (cobimetinib)
  • 7. encorafenib
  • 8. Imlygic (talimogene laherparepvec)
  • 9. Keytruda (pembrolizumab)
  • 10. Mekinist (trametinib)
  • 11. Opdivo (nivolumab)
  • 12. Tafinlar (dabrafenib)
  • 13. Yervoy (ipilimumab)
  • 14. Zelboraf (vemurafenib)
  • 15. Primary Research Methodology

TREATMENT: MELANOMA

  • 16. Executive Summary
  • 17. Primary Research Methodology.
  • 18. Disease Definition and Diagnosis
  • 19. Patient Segmentation
  • 20. Country Treatment Trees
  • 21. Current Treatment Options
  • 22. Prescribing Trends

EPIDEMIOLOGY: MELANOMA

  • 23. Executive Summary
  • 24. Disease Background
  • 25. Sources and Methodology
  • 26. Forecast
  • 27. Epidemiologist Insight
  • 28. Strengths and Limitations

MARKETED DRUGS: MELANOMA

  • 29. Executive Summary
  • 30. Product Overview
  • 31. Product profile: Cotellic
  • 32. Product profile: Imlygic
  • 33. Product profile: Keytruda
  • 34. Product profile: Mekinist
  • 35. Product profile: Opdivo
  • 36. Product profile: Tafinlar
  • 37. Product profile: Yervoy
  • 38. Product profile: Zelboraf

PIPELINE: MELANOMA

  • 39. Executive Summary
  • 40. Clinical Pipeline Overview
  • 41. Product profile (late stage): binimetinib
  • 42. Product profile (late stage): encorafenib
Back to Top